Global
中文
EN
About
Development milestones
Mission&Vision
Founder
Research Achievement
Technical platform
Single domain antibody
Five core technology platforms
Product pipeline
Business cooperation
Product Authorization
Joint research and development
External service
Career development
Our Story
Social Recruitment
News
Company News
Media
Contact Us
Company Address
Online Message
×
Home
中文
EN
About
About Novamab
Technical platform
Product pipeline
Business cooperation
Market target layout
Strategic Cooperation
Career development
News
Company News
Media
Contact Us
About
Committed to the development
of innovative single domain antibody drugs
About Novamab
Scientific research papers
Up to now, the R&D team of Novamab Biology has published several research papers in influential journals.
2022-07-22
Evaluation of SARS-CoV-2-neutralizing Nanobody Using Virus Receptor Binding Domain Administered Model Mice-Research-2022
Published on:
Research (Wash D C). 2022 Jul 22;2022:9864089
More
2022-06-08
Nanobody-based label-free photoelectrochemical immunoassay for highly sensitive detection of SARS-CoV-2 spike protein
Published on:
Analytica chimica acta. 2022 Jun 8;1211:339904
More
2022-01-11
Preclinical evaluation of [99mTc]Tc-labeled anti-EpCAM nanobody for EpCAM receptor expression imaging by immuno-SPECTCT
Published on:
European Journal of Nuclear Medicine and Molecular Imaging. 2022 May;49(6):1810-1821
More
2021-01-31
A potent neutralizing nanobody against SARS-CoV-2 with inhaled delivery potential
Published on:
MedComm (2020). 2021 Mar;2(1):101-113
More
2020-10-16
Nuclear imaging-guided PD-L1 blockade therapy increases effectiveness of cancer immunotherapy
Published on:
Journal for ImmunoTherapy of Cancer. 2020 Nov;8(2):e001156
More
2020-10-15
A novel bispecific nanobody with PD-L1/TIGIT dual immune checkpoint blockade
Published on:
Biochemical and Biophysical Research Communications. 2020 Oct 15;531(2):144-151
More
Total 19
1
2
3
4